Current and historical daily PE Ratio for Eagle Pharmaceuticals Inc (
FRA:1E6
) from 2014 to Jun 12 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Eagle Pharmaceuticals stock (FRA:1E6) PE ratio as of Jun 12 2024 is 4.04.
More Details
Eagle Pharmaceuticals Inc (FRA:1E6) PE Ratio (TTM) Chart
Eagle Pharmaceuticals Inc (FRA:1E6) PE Ratio (TTM) Historical Data
View and export this data going back to 2014. Start your Free Trial
Total 1265
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| Eagle Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-12 | 4.0 | 2024-04-09 | 5.5 |
| 2024-06-11 | 4.0 | 2024-04-08 | 5.7 |
| 2024-06-10 | 4.2 | 2024-04-05 | 5.8 |
| 2024-06-07 | 4.1 | 2024-04-04 | 5.4 |
| 2024-06-06 | 4.4 | 2024-04-03 | 5.0 |
| 2024-06-05 | 3.9 | 2024-04-02 | 5.3 |
| 2024-06-04 | 4.2 | 2024-03-28 | 5.6 |
| 2024-06-03 | 3.9 | 2024-03-27 | 5.7 |
| 2024-05-31 | 3.8 | 2024-03-26 | 5.7 |
| 2024-05-30 | 3.7 | 2024-03-25 | 5.7 |
| 2024-05-29 | 4.3 | 2024-03-22 | 5.8 |
| 2024-05-28 | 4.1 | 2024-03-21 | 6.3 |
| 2024-05-27 | 4.1 | 2024-03-20 | 6.1 |
| 2024-05-24 | 4.2 | 2024-03-19 | 6.2 |
| 2024-05-23 | 4.3 | 2024-03-18 | 6.7 |
| 2024-05-22 | 4.9 | 2024-03-15 | 6.6 |
| 2024-05-21 | 5.1 | 2024-03-14 | 6.6 |
| 2024-05-20 | 5.3 | 2024-03-13 | 6.3 |
| 2024-05-17 | 5.3 | 2024-03-12 | 6.5 |
| 2024-05-16 | 5.1 | 2024-03-11 | 6.8 |
| 2024-05-15 | 5.2 | 2024-03-08 | 7.0 |
| 2024-05-14 | 5.0 | 2024-03-07 | 7.0 |
| 2024-05-13 | 5.1 | 2024-03-06 | 7.2 |
| 2024-05-10 | 5.2 | 2024-03-05 | 7.0 |
| 2024-05-09 | 5.3 | 2024-03-04 | 7.2 |
| 2024-05-08 | 5.3 | 2024-03-01 | 6.5 |
| 2024-05-07 | 5.1 | 2024-02-29 | 7.0 |
| 2024-05-06 | 5.0 | 2024-02-28 | 7.2 |
| 2024-05-03 | 5.0 | 2024-02-27 | 7.2 |
| 2024-05-02 | 4.7 | 2024-02-26 | 6.9 |
| 2024-04-30 | 4.6 | 2024-02-23 | 6.5 |
| 2024-04-29 | 4.7 | 2024-02-22 | 7.0 |
| 2024-04-26 | 4.8 | 2024-02-21 | 6.7 |
| 2024-04-25 | 5.1 | 2024-02-20 | 6.7 |
| 2024-04-24 | 5.4 | 2024-02-19 | 6.7 |
| 2024-04-23 | 5.2 | 2024-02-16 | 6.5 |
| 2024-04-22 | 5.2 | 2024-02-15 | 5.9 |
| 2024-04-19 | 5.1 | 2024-02-14 | 5.9 |
| 2024-04-18 | 5.0 | 2024-02-13 | 6.2 |
| 2024-04-17 | 5.3 | 2024-02-12 | 5.9 |
| 2024-04-16 | 5.9 | 2024-02-09 | 5.9 |
| 2024-04-15 | 4.7 | 2024-02-08 | 5.8 |
| 2024-04-12 | 5.4 | 2024-02-07 | 5.5 |
| 2024-04-11 | 5.3 | 2024-02-06 | 6.3 |
| 2024-04-10 | 5.5 | 2024-02-05 | 6.5 |
Eagle Pharmaceuticals Inc (FRA:1E6) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Eagle Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US2697961082
Share Class Description:
FRA:1E6: Ordinary SharesDescription
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers